Olverembatinib is a new third-generation BCR-ABL inhibitor approved in China, offering hope for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients. This groundbreaking drug is included in China’s National Reimbursement Drug List, highlighting its potential to transform cancer treatment. Ascentage Pharma has developed Olverembatinib to address the limited efficacy and high relapse rates of existing